AFP and hepatocellular carcinoma: The 1-year cumulative incidence of HCC were 0.5% (95% CI 0–1.6%) and 12.6% (95% CI 3.1–22.1%) for the groups with AFP level < 10.5 ng/mL and ≥ 10.5 ng/mL at the start of DAA therapy, respectively.